Comment on 'Pembrolizumab hybrid dosing is non-inferior to flat dosing in advanced non-small cell lung cancer: a real-world, retrospective bicenter cohort study'

被引：0
|
作者：
Zhu, Xudong [1 ,2 ]
机构：
[1] China Med Univ, Dalian Univ Technol, Liaoning Canc Hosp & Inst, Dept Gen Surg,Canc Hosp, Shenyang, Liaoning, Peoples R China
[2] Liaoning Prov Key Lab Precis Med Malignant Tumors, Shenyang, Liaoning, Peoples R China
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2025年 / 13卷 / 03期
关键词：
Immunotherapy; Lung Cancer;
D O I：
10.1136/jitc-2025-011845
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-World Data of Nivolumab and Pembrolizumab in Platinum Refractory Advanced Non-Small Cell Lung Cancer: Potential Practical Predictors of Treatment
    Diker, Omer
    Olgun, Polat
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2022, 32 (02): : 93 - 101
  • [42] Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer
    Galan, Rocio Jimenez
    Prado-Mel, Elena
    de Sotomayor, Maria Alvarez
    Martin, Laila Abdel-Kader
    BIOLOGY-BASEL, 2023, 12 (02):
  • [43] A Multicentric, Retrospective, Real-world Study on Immune-related Adverse Events in Patients with Advanced Non-small Cell Lung Cancers Treated with Pembrolizumab Monotherapy
    Lerner, A.
    Lee, A. J. X.
    Yan, H.
    Van Griethuysen, J.
    Bartlett, A. D.
    Veli, M.
    Jiang, Y.
    Luong, M.
    Naban, N.
    Kane, C.
    Conibear, J.
    Papadatos-Pastos, D.
    Ahmad, T.
    Chao, D.
    Anand, G.
    Asghar, U. S.
    CLINICAL ONCOLOGY, 2024, 36 (03) : 193 - 199
  • [44] Pembrolizumab toxicity in non-small cell lung cancer: a retrospective analysis
    Keast, Mary
    Button, Mick
    Case, Amy
    Iqbal, Sahar
    Namelo, Clara
    Powell, Ceri
    Powell, James
    Shaw, Paul
    Cox, Samantha
    LUNG CANCER, 2022, 165 : S37 - S38
  • [45] Lung Cancer Prognostic Index Performance in US Real-World Advanced Non-Small Cell Lung Cancer Patients
    Shah, R.
    John, A.
    Alexander, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S391 - S391
  • [46] Real-world outcomes of patients with non-small cell lung cancer with and without intracranial metastatic disease: A retrospective cohort analysis
    Sherman, M.
    Das, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S414 - S415
  • [47] Real-world survival outcomes of immunotherapy for advanced non-small cell lung cancer: A single-center retrospective review
    Punchhi, Gopika
    Hussein, Abdulkadir
    Kulkarni, Swati
    THORACIC CANCER, 2024, 15 (05) : 394 - 401
  • [48] Real World Comparison of Gefitinib, Afatinib, Erlotinib, and Osimertinib in Advanced Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Cohort Study
    Peragine, C.
    Bedi, D.
    Kolko, T.
    Thawer, A.
    Cheng, S.
    Doherty, M.
    Menjak, I
    Liu, G.
    DeAngelis, C.
    CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2021, 74 (02): : 176 - 176
  • [49] REAL-WORLD COSTS OF LABORATORY TESTS FOR NON-SMALL CELL LUNG CANCER
    van der Linden, N.
    Smit, E. F.
    Uyl-De Groot, C. A.
    VALUE IN HEALTH, 2014, 17 (07) : A622 - A623
  • [50] Update on real-world efficacy of anlotinib in non-small cell lung cancer
    Gao, Junzhen
    Xu, Yan
    Liu, Yonggang
    Liang, Li
    Yu, Yan
    Zhao, Dahai
    Jin, Jiahui
    Wang, Mengzhao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345